A Decade of Microbiome Breakthroughs: From Scientific Insight to Scalable Therapeutics
Over the past ten years, the microbiome field has rapidly evolved from an emerging scientific opportunity into a commercially validated pillar of modern biopharma innovation. What began as early exploration into gut flora, dysbiosis and live biotherapeutic products (LBPs) has now progressed into a robust pipeline of regulated, clinically validated, GMP-manufactured microbiome therapeutics. Fueled by advances in next generation sequencing, bioinformatics, precision engineering and translational microbiology, the industry has unlocked new applications across infectious disease, immunology, oncology, metabolic disorders, women’s health and more. As regulatory frameworks mature and pharma investment accelerates, the next decade promises scalable manufacturing, personalised microbiome interventions, engineered consortia and global commercial launches, cementing the microbiome as a transformative modality within the biotech and pharma landscape.
2015 – The Dawn of the Microbiome Therapeutics Era
- The microbiome field transitions from academic curiosity to a potential therapeutic frontier.
- Early ventures like Seres Therapeutics and Rebiotix secure major investments, signalling commercial confidence in microbiome-based interventions.
- Initial focus: restoring gut flora and understanding dysbiosis in gastrointestinal disease.
2017 – Expanding Horizons Beyond the Gut
- Researchers uncover key links between the gut microbiome and metabolic, neurological, and immunological disorders.
- Start-ups and pharma begin exploring the gut-brain axis, autoimmune disease, and oncology applications.
2018 – Investment & Industrial Scale-Up
- Venture capital funding for microbiome start-ups surpasses $1 billion globally.
- Advances in sequencing and bioinformatics drive a more mechanistic understanding of host-microbe interactions.
- Manufacturing and GMP scale-up become key industry priorities.
-
A notable highlight came at the Microbiome Skin Health and Dermatology conference, part of the Hanson Wade Microbiome Movement Series held from September 10th to 12th, 2018. Richard Gallo (UCSD) introduced the hologenome concept and emphasised targeted microbial design for skin disease, helping shape early industry thinking around precision microbiome therapeutics in dermatology.
2019 – Regulatory & Analytical Rigor
- Agencies like the FDA and EMA release draft guidance on live biotherapeutic products (LBPs).
- Standardisation efforts emerge around characterisation, potency, and quality control of microbiome-based drugs.
- The field begins shifting focus from correlation to causation and reproducibility.
- The 3rd Annual Microbiome Movement - Drug Development Summit ran in January 2019.
2020 – Resilience Amid Global Disruption
- Despite the pandemic, microbiome research remains robust, with new insights into how microbial diversity influences immune response.
- Growing interest in the microbiome’s role in viral susceptibility and vaccine efficacy.
2021 – Clinical Validation & Readouts
- Landmark phase III results in C. difficile infection from Seres Therapeutics and Rebiotix validate microbiome therapeutics as a new class of medicine.
- Industry focus expands toward precision formulation, delivery, and combination therapy strategies.
-
With the second wave of COVID-19, the Microbiome Movement Summit 2021 was held online from 29th June to 1st July 2021 — and we’ve even pulled out a promotional banner from our archives!
2022 – Beyond the Gut: New Indications Emerge
- Trials advance in dermatology, oncology, metabolic disease, and women’s health.
- Growing focus on mechanistic biomarkers to predict clinical response.
- The 2022 Microbiome Movement event was also held online, and the banner on the right, showing the brochure cover, comes straight from our archives.
2023 – Maturing Science Meets Market Reality
- Increased scrutiny on clinical efficacy, scalability, and reimbursement models.
- M&A activity and partnerships accelerate as pharma integrates microbiome approaches into broader pipelines.
- Next-generation modalities - postbiotics, phage therapies, and engineered consortia - enter the spotlight.
-
The 2023 Microbiome Movement Summit was held in person, allowing attendees to reconnect, enjoy face-to-face networking, and celebrate the return of live interactions within the microbiome community.
2024–2025 – From Discovery to Deliverables
- The field’s focus shifts decisively toward commercial excellence, cross-indication expansion, and approval of these therapeutics internationally.
- MaaT Pharma submitted a Marketing Authorization Application to the European Medicines Agency earlier in June of 2025, marking the first potential commerical launch of a microbiome therapeutic in Europe.
- As we celebrate a decade of the Microbiome Movement in Europe, the community continues driving the science forward - from bench to bedside, and from discovery to global impact.
